Analytics
A leading Geman generics manufacturer Stada that it is in-licensing a biosimilar of Forteo
A leading Geman generics manufacturer Stada announced on October 13, 2014 that it is in-licensing a biosimilar of Forteo (teriparatide) from Richter-Helm BioTec. It will launch the product in Europe in 2019 after the patent on Eli Lilly’s original Forteo expires in December 2018. Teriparatide is a recombinant form of a human parathyroid…
Read moreWorld pharmaceutical market may reach 1 trillion dollars this year
Thomson Reuters forecasts world pharma market to reach 1 trillion dollars this year.
Read moreHimira’s biosimilar successfully passes clinical trials
AbbVie’s Humira is the world’s top-selling drug with this year’s second quarter revenue of $3.29 bln according to IMS Health.
Read moreEuropean generics industry is undergoing a serious change
European generics manufacturers are switching to biosimilars. Two thirds of drugs losing patent protection in 2014-2020 are biologics or specialty products.
Read moreBIOCAD is developing a new drug for melanoma treatment
At this time BIOCAD is studying several molecules. The most successful candidate will become a new product in 2018-2019.
Candidate molecules are monoclonal antibodies to PD-1 antigen that stimulate patient immune system to destroy cancer cell. BIOCAD is planning to launch 1-2 new generation drugs every year starting in…
Read more245 companies worldwide are developing 700 biosimilars
The market is biologics may exceed 250 bln USD by 2020. Biosimilars, copies of biologics, are becoming more popular. According to Reuters 245 companies worldwide are currently developing 700 biosimilars.
Biggest players are Teva, Sandoz, Pfizer, and Amgen. Biosimilars popularity can be explained by their profitability:…
Read moreBiologics with a total of $67 bln in global sales will lose patent protection by 2020
Twelve biologics with total global sales of $67 bln will meet generics competition by 2020.
Read moreCommon drug registration rules for countries in the Customs Union are anticipated by 2016
Currently drugs are the only commodity that cannot move freely between Russia, Belarus and Kazakhstan.
Read more